Manufacturing hurdles are just one challenge the industry must overcome to commercialize personalized mRNA cancer vaccines.
Oncology still accounts for nearly two out of five pipeline drugs, while obesity entered the top 10 indications and one-third ...
Merck pursues new cancer combinations, prediction markets put pharma’s confidential information in focus and personalized ...
CAR-T’s commercial challenge isn’t making bigger batches. It’s making thousands of patient-specific manufacturing runs behave ...
The Alzheimer’s space has really got a fire under it,” says one analyst. But can the momentum deliver better drugs?
Plump joined Takeda during a turbulent period, pushed the company to work more closely with young biotechs and will leave it ...
Wall Street analysts believe that a more cautious approach to manufacturing, study enrollment and side effect management ...
After two notable failures, the social anxiety R&D space gained a major player when Eli Lilly agreed to acquire AtaiBeckley ...
As betting expands into clinical trial outcomes, drugmakers may need to look beyond employees and scrutinize outside partners ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results